Apple and Masimo's patent and trade secret dispute has intensified through lawsuits as Apple defends its innovations and ...

Medical-device maker said Joe Kiani, who previously informed the board of his decision to resign as chief executive, has been ...

The consensus rating for Masimo is Buy, based on 2 analyst ratings. With an average one-year price target of $167.5, there's a potential 16.14% upside.

Buying $1000 In MASI: If an investor had bought $1000 of MASI stock 10 years ago, it would be worth $5,655.84 today based on a price of $144.22 for MASI at the time of writing.

Apple has sought an injunction against health tech maker Masimo’s own smart watches, but it also netted the bare minimum for ...

Apple convinced a federal jury on Friday that early versions of health monitoring tech company Masimo's smartwatches infringe ...

Masimo filed a lawsuit against its founder and former CEO Joe Kiani and investment firm RTW Investments, accusing them of ...

A federal jury Friday ruled that Masimo's smartwatches infringed on Apple Watch patents, but awarded Apple just $250 in ...

A federal jury ruled Friday that Masimo smartwatches infringed Apple patents, but Apple isn’t getting a big payday. Bloomberg ...

We recently published a list of 8 Most Promising Medical Stocks According to Hedge Funds. In this article, we are going to ...

The legal battle between Apple and medical technology company Masimo rages on, with the bigger company — sorta, kinda — ...